Skip to Content
Morningstar

Annexon Inc Ordinary Shares ANNX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$4.45 +0.01 (0.23%)
View Full Chart
As of Delayed Price Pre-Open: $4.40 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
ANNX is trading at a 71% discount.
Price
$4.54
Fair Value
$82.98
Uncertainty
Extreme
1-Star Price
$698.20
5-Star Price
$3.66
Economic Moat
Sdyys
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANNX is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$4.44
Day Range
$4.41–4.85
52-Week Range
$1.57–8.40
Bid/Ask
$4.35 / $4.40
Market Cap
$400.61 Mil
Volume/Avg
5,557 / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
71
Website
https://www.annexonbio.com

Comparables

Valuation

View More
Metric
ANNX
CBAY
VRDN
Price/Earnings (Normalized)
 ———
Price/Book Value
 1.3912.652.99
Price/Sales
 —111.011,857.18
Price/Cash Flow
 ———
Price/Earnings
ANNX
CBAY
VRDN

Financial Strength

Metric
ANNX
CBAY
VRDN
Quick Ratio
 14.4910.7017.93
Current Ratio
 14.7210.9618.26
Interest Coverage
 —−5.27−137.76
Quick Ratio
ANNX
CBAY
VRDN

Profitability

Metric
ANNX
CBAY
VRDN
Return on Assets (Normalized)
 −45.04%−30.06%−42.76%
Return on Equity (Normalized)
 −55.89%−51.97%−82.42%
Return on Invested Capital (Normalized)
 −52.38%−30.87%−50.70%
Return on Assets
ANNX
CBAY
VRDN
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRPphczprqGbhph$562.4 Bil
VRTX
Vertex Pharmaceuticals IncDngvkcfgWrqmzd$103.6 Bil
REGN
Regeneron Pharmaceuticals IncJjprtrgkPjlyvw$99.5 Bil
MRNA
Moderna IncYgzlwnbvwTbyv$38.8 Bil
ARGX
argenx SE ADRVntmygycBtjw$22.3 Bil
BNTX
BioNTech SE ADRQbsxcrlrVmdw$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncRzyvknntjCpkyl$18.2 Bil
BMRN
Biomarin Pharmaceutical IncVpwqgywvzFrypzt$17.3 Bil
RPRX
Royalty Pharma PLC Class AGbrjjznbJwgvxg$12.5 Bil
INCY
Incyte CorpCjcbfqcmqTlfckrh$11.6 Bil

Sponsor Center